Following a four year tour in the U.S. Air force Mr. Mesa joined Rodana Research Corporation and until recently was continuously employed by Rodana and its successor organizations including: Survival Technology Inc., Meridian Medical Technologies Inc., King Pharmaceuticals Inc. and Pfizer. In 2011, Mr. Mesa left Meridian/Pfizer and formed Mesa Science Associates.
Mr. Mesa served as Meridian Medical Technologies primary interface with the U.S. Military Chemical Biologic Medical Systems/Medical Identification and Treatment Systems (CBMS/MITS) for pharmaceutical and drug delivery programs. He was the principal investigator for the development of the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). His work with the ATNAA program eventually led to an FDA approved companion product, The DuoDote© Auto-Injector. The DuoDote© is now available in the U.S. for use by first responders in the event of a chemical attack against the civilian population. Most recently he successfully managed the midazolam based Advanced Anti-Convulsant (AAS) clinical program intended for military use.
In the civilian arena Mr. Mesa played a key role in the development of both the original and the next generation EpiPen© and EpiPen Jr© auto-injectors. In the epilepsy field he managed the development of auto-injectors and training materials for two important epilepsy studies: the NIH funded RAMPART© Study and the King Pharmaceuticals RESCUE© Study.